This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taraboletti, G. Articles by Giavazzi, R. Search for Related Content PubMed PubMed Citation Articles by Taraboletti, G. Articles by Giavazzi, R.

Antiangiogenic and Antitumor Activity of IDN 5390, a New Taxane Derivative¹

Department of Oncology, Mario Negri Institute for Pharmacological Research, 24125 Bergamo [G. T., G. M., M. R., M. P., M. T., P. B., M. I. N., R. G.]; Istituto di Anatomia Patologica Veterinaria e Patologia Aviare, Università degli Studi, 20133 Milan [P. R., E. S.]; Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, Chieti [C. R.]; and INDENA SpA, 20139 Milan [E. B., P. M., A. R.], Italy

Purpose: We previously reported that paclitaxel, a microtubule-stabilizing drug, inhibited angiogenesis, mainly by inhibiting endothelial cell motility (D. Belotti et al., Clin. Cancer Res., 2: 1843–1849, 1996). The aim of this study was to select a taxane with little cytotoxicity but with antimotility and hence antiangiogenic activity.

Experimental Design: Different taxanes, seco derivatives, and 14-ß-hydroxy-10-deacetyl baccatin III derivatives were tested for their effects on the proliferation and motility of human umbilical vein endothelial cells. The antiangiogenic and antineoplastic activities of the compound selected from this screening were further investigated in experimental models in vitro and in vivo.

Results: From the screening of different taxanes, we selected IDN 5390, a seco derivative that showed potent antimotility activity and less cytotoxicity than paclitaxel. In comparable experimental conditions, IDN 5390 inhibited endothelial cell migration without affecting proliferation. This compound dose-dependently inhibited the capacity of human umbilical vein endothelial cells plated on Matrigel to organize into a network of cords. In vivo, IDN 5390 significantly inhibited fibroblast growth factor-2-induced angiogenesis in Matrigel implants. Daily treatment with IDN 5390 in mice bearing established lung micrometastases from the B16BL6 murine melanoma caused a reduction in the size of metastases. Finally, IDN 5390 slowed the s.c. growth of the paclitaxel-resistant human ovarian carcinoma, 1A9/PTX22, xenografted in nude mice.

Conclusions: The seco derivative IDN 5390 might represent the prototype of a new class of taxane derivatives with antiangiogenic properties.

This article has been cited by other articles:

				S. Prislei, S. Mozzetti, F. Filippetti, M. De Donato, G. Raspaglio, L. Cicchillitti, G. Scambia, and C. Ferlini From plasma membrane to cytoskeleton: a novel function for semaphorin 6A Mol. Cancer Ther., January 1, 2008; 7(1): 233 - 241. [Abstract] [Full Text] [PDF]

				R. Frapolli, E. Marangon, M. Zaffaroni, T. Colombo, C. Falcioni, R. Bagnati, M. Simone, M. D'Incalci, C. Manzotti, G. Fontana, et al. Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors Drug Metab. Dispos., December 1, 2006; 34(12): 2028 - 2035. [Abstract] [Full Text] [PDF]

				G. F. Weber, F. C. Gaertner, W. Erl, K.-P. Janssen, B. Blechert, B. Holzmann, H. Weighardt, and M. Essler IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase J. Immunol., December 1, 2006; 177(11): 8266 - 8272. [Abstract] [Full Text] [PDF]

				E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]

				G. Taraboletti, G. Micheletti, R. Dossi, P. Borsotti, M. Martinelli, F. Fiordaliso, A. J. Ryan, and R. Giavazzi Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies Clin. Cancer Res., April 1, 2005; 11(7): 2720 - 2726. [Abstract] [Full Text] [PDF]

				C. Ferlini, G. Raspaglio, S. Mozzetti, L. Cicchillitti, F. Filippetti, D. Gallo, C. Fattorusso, G. Campiani, and G. Scambia The Seco-Taxane IDN5390 Is Able to Target Class III {beta}-Tubulin and to Overcome Paclitaxel Resistance Cancer Res., March 15, 2005; 65(6): 2397 - 2405. [Abstract] [Full Text] [PDF]

				M. R. Bani, M. I. Nicoletti, N. W. Alkharouf, C. Ghilardi, D. Petersen, E. Erba, E. A. Sausville, E. T. Liu, and R. Giavazzi Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts Mol. Cancer Ther., February 1, 2004; 3(2): 111 - 121. [Abstract] [Full Text] [PDF]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				G. Micheletti, M. Poli, P. Borsotti, M. Martinelli, B. Imberti, G. Taraboletti, and R. Giavazzi Vascular-targeting Activity of ZD6126, a Novel Tubulin-binding Agent Cancer Res., April 1, 2003; 63(7): 1534 - 1537. [Abstract] [Full Text] [PDF]